Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IN8BIO, INC. (INAB)

IN8bio Q2 net loss narrows to $4.8 million; cash reaches $18.0 million

Positive Impact 3 of 5 earnings Written later

IN8bio reported second-quarter 2026 results, with a net loss of $4.8 million, or $0.25 per share, versus $5.1 million, or $1.24 per share, a year earlier. Cash was $18.0 million at June 30, 2026, up from $13.2 million a year earlier but down from $27.1 million at December 31, 2025, which shareholders should weigh against the company's continued cash needs.

Key points

  • Net loss of $4.8 million, or $0.25 per share, for the quarter ended June 30, 2026, compared with $5.1 million, or $1.24 per share, a year earlier
  • R&D expenses of $2.5 million were flat year over year; G&A expenses fell to $2.4 million from $2.7 million
  • Cash of $18.0 million at June 30, 2026, compared with $13.2 million a year earlier and $27.1 million at December 31, 2025
  • Weighted-average shares outstanding were 19,467,091 for the quarter, versus 4,119,153 a year earlier

The filing

CompanyIN8BIO, INC. (INAB)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:05 PM ET
Accession number0001193125-26-337944

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.